NCHR Comments to EPA on Principles to Applying Systematic Review in TSCA Risk Evaluations

August 16, 2018. Protecting the public health requires that EPA’s draft guidance for applying a systematic review process for risk evaluations is scientifically valid, reliable, and accepted by the scientific community. It should consider the totality of the scientific evidence without often irrelevant or industry-centric requirements that would reduce the impact of high quality sources or exclude them.

Read More »

NCHR Testimony on Omadacycline for Skin Infections and Pneumonia

August 8, 2018. If omadacycline is no better than some drugs on the market, and may be less safe or less effective for older patients, those with more serious infections, and patients with diabetes and lung disease, it is important to conduct further studies to know whether they should be excluded from the indication or not.

Read More »

NCHR Testimony of TIRF REMS

August 3, 2018. TIRFs provide important options for cancer patients dealing with pain. However, we all know that they carry very serious risks and that’s why we need REMS that protect patients’ these risks.  These REMS are not working as well as the should to protect patients and need to be approved.

Read More »
Page 10 of 109« First...89101112...203040...Last »